B7-H1在卵巢癌组织中表达的临床意义

Expression and Clinical Significance of B7-H1 in Ovarian Cancer

目的探讨B7-H1在卵巢癌组织中表达的临床意义。方法将收治的112例上皮性卵巢癌及10例良性卵巢囊肿的组织蜡块制作成组织芯片,免疫组化检测芯片协同刺激分子B7-H1的表达情况,χ2检验B7-H1表达水平与患者临床病理参数的关系。生存分析采用Kaplan-Meier法和Log-rank检验及多因素COX回归。结果 B7-H1在良性卵巢囊肿中均为低表达,在卵巢癌组织中高表达率为55.4%(62/112);其表达水平与患者年龄、组织类型、细胞分化、肿瘤大小及是否合并CA125升高无关(P>0.05),而与患者FIGO分期及是否转移密切相关(P<0.05);B7-H1高表达组与低表达组患者无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)比较差异均有统计学意义(χ2值分别为24.9和17.51,P值均<0.001)。COX回归分析表明,B7-H1表达水平和FIGO分期是影响患者生存的独立预后因素。结论卵巢癌组织中B7-H1的表达水平与预后差和生存期短相关,可为卵巢癌的免疫靶向治疗提供思路。

Objective To investigate the expression and clinical significance of B7-H1 in ovarian cancer. Methods 112 biopsies from patients with epithelial ovarian cancer（EOC） and 10 specimens from ovarian benign neoplasm were processed into tissue chips. The expression of B7-H1 were detected by immunohistochemieal method and its relationship with patients＇clinical parameter were tested by Pearson Chi-Square. Survival curves were constructed using the Kaplan-Meier method and the log-rank test. The independent prognostic factors were evaluated by using the Cox regression model. Results The BT-H1 high expression rates were 0 in benign ovarian neoplasm tissues and 55.4% （62/112） in EOC tissues. The level of B7-H1 expression was positively correlated with clinical stage and distant metastases（ P 〈0. 05 ）. No relationship was observed between the expression of B7-I-I1 and age, primary tumor size, primary tumor classification, histological grade and the level of blood CA125 （P 〉 0.05 ）. The progression-free survival（PFS） and the overall survival（OS） were significantly lower in patients with B7-H1 high expression than in those with B7-H1 low expression. Multi-variable analysis revealed that the expression of B7-H1 and the clinical stage could be regarded as the independent factor in evaluating the prognosis of EOC patients. Conclusion The level of B7-H1 expression in EOC tissues is significantly correlated with the poor prognosis and relapse rate. B7-H1 might be a beneficial target for immuno- therapy in EOC patients.